BACKGROUND Reducing the levels of triglycerides and triglyceride-rich lipoproteins
remains an unmet clinical need. Olezarsen is an antisense oligonucleotide targeting …

Background Persistent chylomicronemia is a genetic recessive disorder that is classically
caused by familial chylomicronemia syndrome (FCS), but it also has multifactorial causes …

There is a gap of knowledge about the clinical and pathophysiological implications resulting
from the interaction between primary hyperlipidemias and type 2 diabetes (T2D). Most of the …

Introduction Dyslipidemia plays a crucial role in the development of atherosclerotic
cardiovascular diseases. Areas covered This article explores the emerging therapeutic …

In recent years, novel apoC3 inhibitor therapies for the treatment of hypertriglyceridemia
have been developed and assessed through phase II and III clinical trials. The objective of …

Nucleic acid-based therapies are being rapidly developed for prevention and management
of cardiovascular diseases (CVD). Remarkable advancements have been achieved in the …

ABSTRACT Introduction Apolipoprotein (apo) C-III, a key regulator of plasma triglyceride
(TG) levels, is a prime candidate for the treatment of hypertriglyceridemia (HTG), prevention …

Abstract Purpose of Review Multiple agents are being developed that inhibit apolipoprotein
(apo) C-III. This state-of-the-art review examines their potential for atherosclerotic …

Apolipoprotein C3 (APOC3) plays a critical role in regulating triglyceride levels and serves
as a key predictor of cardiovascular disease (CVD) risk, particularly in patients with diabetes …

Introduction Hypercholesterolemia and other lipid disorders are major causes of
atherosclerotic cardiovascular disease (ASCVD). Statins have been the mainstay of lipid …